394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic

Abstract

Abstract Background AZD7442 is a combination of two half-life extended monoclonal antibodies, tixagevimab and cilgavimab. A population pharmacokinetic (popPK) model for AZD7442 included interim data from phase 3 trials in pre-exposure prophylaxis (PreP; PROVENT), post-exposure prophylaxis (STORMCHASER), and treatment of mild-to-moderate COVID-19 (TACKLE) in adults. This popPK model facilitated inclusion of adolescents in the AZD7442 label, the decision to increase the recommended PreP dose of AZD7442 in response to evolving SARS-CoV-2 variants, and selection of doses for a pediatric study (TRUST). Upon completion of the adult phase 3 studies, the popPK model was updated to include data from eight studies. Methods The final popPK analysis included 4940 adult participants from North and South America, Europe, and Asia. To predict the PK of AZD7442 in pediatric patients, the effect of post-menstrual age on clearance was incorporated into the model. Results The PK of AZD7442, tixagevimab, and cilgavimab were very similar and dose-proportional. PopPK analyses found no difference in AZD7442 PK between PreP and treatment (Figure 1). The final AZD7442, tixagevimab, and cilgavimab models included body weight, sex, age, BMI, Black race, and site of intramuscular administration as covariates; none of these were clinically relevant nor required dose adjustment. When interim TRUST (pediatric) data became available, popPK predictions were compared to observed serum PK data (Figure 2). Good agreement was observed, confirming appropriateness of dosing adolescents ≥40kg with the same dosing regimen as adults, and adequate characterization of AZD7442 PK in pediatric participants. Safety data from TRUST and adult studies were comparable. Conclusion The PK of AZD7442, cilgavimab, and tixagevimab are comparable and follow linear kinetics with an extended half-life, allowing for prolonged duration of protection. AZD7442 PK is comparable across indications and between adults and pediatric populations. PopPK analyses facilitated rapid decision-making during the COVID-19 pandemic, including accelerating access to AZD7442 by adolescent patients ahead of the availability of pediatric clinical data. Disclosures Lindsay E. Clegg, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Oleg Stepanov, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Henning Schmidt, PhD, AstraZeneca: Employed by IntiQuan, which received payment from AstraZeneca for work involved in this analysis Ventakesh Pilla Reddy, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Weifeng Tang, MD, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Michael Gibbs, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Sangeeta Sedani, MSc, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Antonella Nadia Tuillio, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Sam Sadow, MA, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Nuria Martinez-Alier, PhD, AstraZeneca: Employee|AstraZeneca: Employement|AstraZeneca: Stocks/Bonds|AstraZeneca: Stocks/Bonds Taylor Cohen, PhD, AstraZeneca: Employement|AstraZeneca: Stocks/Bonds Saul N. Faust, FRCPCH PhD, AstraZeneca, Janssen, Pfizer, Moderna, GlaxoSmithKline, Novavax, Sanofi, Seqirus, Medimmune, Merck, MSD, Iliad and Valneva: Advisor/Consultant|AstraZeneca, Janssen, Pfizer, Moderna, GlaxoSmithKline, Novavax, Sanofi, Seqirus, Medimmune, Merck, MSD, Iliad and Valneva: Investigator Mark T. Esser, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Mats Någård, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds